

## Central Lancashire Online Knowledge (CLoK)

Title	Metabolomic changes in tear fluid following zinc biofortification in the BiZiFED nutritional study: a feasibility study
Туре	Article
URL	https://clok.uclan.ac.uk/id/eprint/52929/
DOI	https://doi.org/10.3389/fmolb.2024.1421699
Date	2024
Citation	Brown, Connor N., Shahzad, Babar, Zaman, Mukhtiar, Pan, Xiaobei, Green, Brian D., Lowe, Nicola M and Lengyel, Imre (2024) Metabolomic changes in tear fluid following zinc biofortification in the BiZiFED nutritional study: a feasibility study. Frontiers in Molecular Biosciences, 11.
Creators	Brown, Connor N., Shahzad, Babar, Zaman, Mukhtiar, Pan, Xiaobei, Green, Brian D., Lowe, Nicola M and Lengyel, Imre

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.3389/fmolb.2024.1421699

For information about Research at UCLan please go to <a href="http://www.uclan.ac.uk/research/">http://www.uclan.ac.uk/research/</a>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>

### Check for updates

### **OPEN ACCESS**

EDITED BY Michal Ciborowski, Medical University of Bialystok, Poland

REVIEWED BY Simone Zuffa, University of California, San Diego, United States Nikolai Kolba, Cornell University, United States

\*CORRESPONDENCE Imre Lengyel, ⊠ i.lengyel@qub.ac.uk

RECEIVED 22 April 2024 ACCEPTED 28 August 2024 PUBLISHED 10 September 2024

#### CITATION

Brown CN, Shahzad B, Zaman M, Pan X, Green BD, Lowe NM and Lengyel I (2024) Metabolomic changes in tear fluid following zinc biofortification in the BiZiFED nutritional study: a feasibility study. *Front. Mol. Biosci.* 11:1421699. doi: 10.3389/fmolb.2024.1421699

### COPYRIGHT

© 2024 Brown, Shahzad, Zaman, Pan, Green, Lowe and Lengyel. This is an open-access article distributed under the terms of the **Creative Commons Attribution License (CC BY)**. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Metabolomic changes in tear fluid following zinc biofortification in the BiZiFED nutritional study: a feasibility study

Connor N. Brown<sup>1</sup>, Babar Shahzad<sup>2</sup>, Mukhtiar Zaman<sup>3</sup>, Xiaobei Pan<sup>4</sup>, Brian D. Green<sup>4</sup>, Nicola M. Lowe<sup>5</sup> and Imre Lengyel<sup>1</sup>\*

<sup>1</sup>Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom, <sup>2</sup>Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan, <sup>3</sup>Department of Pulmonology, Rehman Medical Institute, Peshawar, Pakistan, <sup>4</sup>Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom, <sup>5</sup>Centre for Global Development, School of Sport and Health Sciences, University of Central Lancashire, Preston, United Kingdom

**Background:** Biofortified Zinc Flour to Eliminate Deficiency in Pakistan (BiZiFED) is a nutritional research program that evaluates the impact of consuming zinc biofortified wheat flour on zinc status and associated health outcomes of vulnerable communities in northwest Pakistan. Measuring zinc status from blood samples is fraught with problems. This feasibility study evaluated whether metabolite changes in tear biofluids could be used to understand zinc status.

**Methods:** Zinc deficiency is particularly prevalent amongst the female population in Pakistan. Therefore, a crossover trial was developed in which 25 women of reproductive age received standard, wheat flour, and another 25 received zinc-biofortified wheat flour for 8 weeks. At the end of this period, the nutritional intervention was switched between the groups for another 8 weeks. Tear biofluid was collected using Schirmer strips at baseline and after 8 and 16 weeks. Metabolomic analysis was conducted using the MxP<sup>®</sup> Quant 500 kit on the tear biofluid from a subset of the study participants.

**Results:** Two metabolites had a significantly negative correlation with plasma zinc concentration: tiglylcarnitine and valine. Compared to baseline metabolite concentrations, acetylcarnitine, glutamine, two lysophosphatidylcholines (lysoPC a C16:0 and lysoPC a C18:1), and four sphingomyelins (SM (OH) C16:1, SM C16:0, SM C16:1, and SM C24:0) were all significantly decreased post-zinc intervention, whilst a ceramide (Cer(d18:1/18:0) was significantly increased.

**Conclusion:** These results highlight the potential of using tear biofluids as an alternative source for metabolomic biomarkers, both for the assessment of the zinc status of individuals enrolled in nutritional studies and for indicating physiological changes that arise from nutritional supplementation.

KEYWORDS

zinc, nutrition, tear, LC-MS, BiZiFED, metabolomics

### Introduction

Micronutrient deficiencies affect approximately one-third of the global population (Pingault et al., 2017), with significant inequities in the burden of this 'hidden hunger', which particularly affects children and pregnant women in low- and middle-income countries (Wessells and Brown, 2012; Kassebaum et al., 2014; Micha et al., 2020). Amongst the micronutrients, zinc deficiency is well documented in Pakistan, with an average of 22.1% of women at reproductive age reported as being zinc deficient (Pakistan, 2019). Some of the well-documented negative impacts of zinc deficiency are slowed cognitive development, reduced immune competence, and complications during pregnancy and childbirth (Lowe, 2016), along with stunting of physical growth during development. These factors have been shown extensively in one marginalised rural community of Pakistan, the Peshawar community, where there is an above-average level of zinc deficiency in women of reproductive age (Brazier et al., 2020; Pakistan and UNICEF, 2020). The Peshawar community in Khyber Pakhtunkhwa have the highest proportion of children under 5 years of age with stunted growth (Pakistan and UNICEF, 2020), and there is also a correlation between the deficiency in plasma zinc concentration (PZC) and stunting in adolescent girls (aged 16-19 years old) of this community (Liere et al., 2017).

Strategies to improve zinc nutrition need to be developed, and work is ongoing to find solutions in the form of supplementation, dietary diversification, fortification, and biofortification. Of these options, fortification and biofortification appear to be the most likely strategies to gain traction as supplementation is often used as a therapeutic rather than a preventative strategy, and dietary diversification would require significant investment and programme development to support changes in food choices and behaviour that are limited by affordability (e-Pact Consortium, 2019; Gupta et al., 2020). Mass fortification involves the addition of micronutrients to food during processing. Fortification of flour with micronutrients (including zinc) at large commercial roller mills has been trialled in Pakistan, but success was limited because half of the population purchases their flour from local mills known as "Chakkis" rather than the large mills that are enrolled in the fortification initiative, thus severely limiting the reach of the program (e-Pact Consortium, 2021).

Biofortification of staple crops can be achieved through either transgenic techniques or conventional breeding to select varieties with naturally high micronutrient content, which can be combined with the addition of micronutrient fertilizer directly to the crop or soil to enhance the micronutrient content of the edible portion. Biofortification has the advantage that, once a high micronutrient variety has been developed, the farmer can retain a portion of the yield each year to use as seed for the following year. Thus, biofortification has the potential to have an impact on micronutrient deficiencies on a population scale. To date, six varieties of zinc biofortified wheat have been released onto the market in Pakistan. The first, known as Zincol-2016, was released in 2016 and was the variety evaluated in the Biofortified Zinc Flour to Eliminate Deficiency in Pakistan (BiZiFED) research program (Lowe et al., 2018, Lowe et al., 2020; Lowe et al., 2022), designed to explore the potential for zinc biofortified wheat to improve dietary zinc and iron intake for, and whether this correlates to functional alterations in the micronutrient status of women of reproductive age and adolescent girls (Lowe et al., 2020).

Zincol-2016 wheat grain, grown with the addition of zinc fertilizer to the soil and leaves, had a significantly elevated zinc concentration compared to standard (control) grain, resulting in a significant increase in the daily zinc intake from the flour compared with control flour, of between 3 and 6 mg per day for white and whole grain flour, respectively. However, it should be noted that this increase in zinc intake did not have a sustained impact on plasma zinc concentration or on fatty acid desaturase and elongase activity (FADS1 and 2), which has been explored as a putative biomarker of zinc status (Knez et al., 2017; Lowe et al., 2022).

Therefore, an alternative, sensitive biomarker is required to monitor better the physiological and biochemical impact of small changes in dietary zinc, such as those achievable through biofortification strategies to overcome these global health challenges. One such source of biomarkers is the tear fluid, which is increasingly being investigated as a non-invasive, cheap, physiologically relevant source of circulating biomarkers.

One of the first exclusive characterisations of the human tear metabolome employed a standard clinical method for tear collection coupled with an analytical platform to characterize the global repertoire of human tear metabolites (Chen et al., 2011). In this study, tears of healthy individuals were collected using the clinically utilized Schirmer strips, separated by ultra-fast liquid chromatography (LC), and analysed by quadrupole time-of-flight tandem mass spectrometry (Q-TOF MS/MS). This set a precedent for what could be achieved in tear metabolome studies, but it was clear that this method did not measure some well-known metabolites (e.g., measurement of glucose and ascorbic acid was affected by background interference).

Very few lipid species were identified, but within the literature, others have identified several classes of lipids using targeted analysis. These include free cholesterol (Borchman et al., 2007), phosphatidylcholines (Borchman et al., 2007; Saville et al., 2010), sphingomyelins (Borchman et al., 2007; Saville et al., 2010), wax esters (Borchman et al., 2007; Lam et al., 2013), lysophosphatidylcholine (Rantamäki et al., 2011; Dean and Glasgow, 2012), triacylglycerides, ceramides, and phosphatidylethanolamines (Dean and Glasgow, 2012). A further study investigated lipid composition during collection with Schirmer strips using untargeted analysis (Lam et al., 2014). Tears were collected by capillary tube or Schirmer strip, and extracted lipids were analysed using HPLC-MS. Over 600 lipid species across 17 lipid classes were detected, most categorized as wax or cholesteryl esters.

Schirmer strip collections yield the highest absolute amounts of lipids and are routinely employed in the clinic. Interestingly, the strips act as a chromatographic system for lipid metabolites (Rantamäki et al., 2011; Lam et al., 2014), whereby the aqueous fraction of the tear travels further along the strip than the non-polar lipids. The strips can accurately represent the lipidomic profile of tears and their relative concentrations when compared to spiking with artificial tear solutions (Lam et al., 2014).

As reviewed elsewhere (Khanna et al., 2022), tear samples appear to be a reasonable reservoir of metabolites. Their collection is non-invasive, and the samples are easy to handle and cheap to transport. These factors indicate that tear sampling could become a reliable source of metabolic markers for ophthalmic and systemic diseases (Cicalini et al., 2019; Valencia et al., 2022; Wen et al., 2023). The aims of this study were threefold: first, to explore the feasibility of using tear biofluid as a source of metabolite biomarkers for human studies and the impact of transport and storage on sample viability; second, to assess whether metabolites in tear biofluid correlate with traditional zinc biomarkers; and thirdly, to assess the response of tear metabolites to small changes in dietary zinc intake across subgroups within a dietary zinc intervention program.

### Materials and methods

### Study location and design

This study was nested within the BiZiFED program, which included a double-blind, individually randomised, placebo-controlled study with cross-over design (Lowe et al., 2018; Ohly et al., 2019). The study was in a community close to the city of Peshawar in the province of Khyber Pakhtunkhwa in northwest Pakistan. This is a rural community where zinc deficiency is widespread and where the plantbased diet has a low zinc bioavailability. The trial was registered with the ISRCTN registry, study ID ISRCTN83678069 and undertaken between October 2017 and February 2018. The lead university (University of Central Lancashire; ethics reference no. STEMH 697 FR) and the collaborating institution in Pakistan, Khyber Medical University, granted ethical approval. The full study protocol has been previously described in detail (Lowe et al., 2022). In brief, 50 households, with at least one 16-49-year-old woman who was neither pregnant nor breastfeeding nor consuming additional nutritional supplementation, were randomly selected for the study. The selected households were provided with either freshly milled Zincol-2016/NR-421 grain (genetically and agronomically Zn-biofortified) or Galaxy-2013 grain (control), with the intention that these were the only flours to be consumed for the duration of the study. A 2-week baseline period was established with control flour before the households were randomly separated into two groups for the purposes of the study (Figure 1), one which received Zincol-2016/NR-421 grain for 8 weeks and then Galaxy-2013 control grain for 8 weeks (study arm 1 (SA1)), whilst the other received Galaxy-2013 control grain for 8 weeks followed by Zincol-2016/NR-421 grain (study arm 2 (SA2)) (Lowe et al., 2018).

### Participant information

At baseline, the characteristics of the study participants were recorded, including socio-economic status indicators and household demographics. In addition, dietary assessment was carried out using 24-h recalls throughout the 18-week study period using the multiple pass method, and detailed recipes for composite meals were collected for accurate curation of ingredients into an appropriate nutrient database. Thorough methodologies and results summarising demographic (Brazier et al., 2020) and dietary results (Lowe et al., 2022) have previously been published.

Where possible, blood was also collected from the study participants at the three time points, to determine plasma zinc concentrations pre- and post-dietary zinc intervention. Briefly, whole blood was collected into trace-element-free anticoagulant tubes and blood plasma was separated through centrifugation. Elemental concentrations of zinc were determined using inductively coupled plasma-mass spectrometry (ICP-MS) and reported recently (Brazier et al., 2020).

### Tear collection

Where possible, tears were collected on Schirmer tear test strips (4701001, Haag-Streit UK Ltd., Essex, UK) from both eyes of the study participants at all three time points. Briefly, the Schirmer strips were folded at the notch, before resting the rounded notch in the inferior conjunctival fornix (inside the lower eyelid) (Supplementary Figure S1A). Participants were given the option to close their eyes. The Schirmer strips were removed when the strips became saturated with tear fluid or once 5 min had passed, whichever came first. The strips were air dried, sealed in an envelope, placed in a Ziploc bag, shipped to Queen's University Belfast (QUB) at ambient temperature, and stored at  $-80^{\circ}$ C before analysis.

### Sample selection

To conduct a metabolomics feasibility and viability assessment from the tear samples obtained as part of the BiZiFED study, five samples were selected randomly from individuals who were initially enrolled on the study program but could not provide tear samples at all three time points. These were compared to freshly collected tear samples obtained from two in-house researchers simultaneously, with one sample collected from each eye from each person. Tears were collected in the same manner as those in the BiZiFED study. Once the tears were collected, the Schirmer strips were air-dried overnight at room temperature before metabolite extraction alongside the five randomly selected stored samples from the BiZiFED participants.

Of the remaining BiZiFED samples, a subset was selected for metabolomics analysis based on the following steps: 1) tear samples from individuals who could provide samples at all three time points were identified (n = 33); 2) tear samples from study participants were selected based on their plasma zinc status at baseline (n = 10). Plasma zinc concentration (PZC) is the most commonly used marker of zinc status (Abdulla, 1983) and a value of 660 µg/L was used as the threshold below which a participant was categorized as zincdeficient (Brown et al., 2004). The methods and results to determine the PZC of BiZiFED study participants have previously been published (Brazier et al., 2020); 3) for LC-MS sample processing, a further 16 were randomly selected from the remaining 23 participants using a random number generator, to provide additional numbers inassessing whether tear metabolites responded to dietary zinc intervention in a larger cohort of individuals.

### Initial metabolite extraction and LC-MS procedure for assessing feasibility and viability of targeted metabolomics on stored tear fluid

To set up the protocol for metabolite extraction, two 4 mm punches were taken from each Schirmer strip



(Supplementary Figure S1B), using a custom-made tool as per Dammeier *et al.* (Dammeier et al., 2018). Amino acids and acylcarnitines were extracted according to the manufacturer's instructions using the MassChrom<sup>®</sup> kit (57000/F, ChromSystems Instruments & Chemicals, Munich, Germany). Once prepared for analysis, the material was reconstituted in 2.5 mM ammonium acetate in 25% methanol (aq) to analyse amino acids, after which the material was further dried down at 60°C and reconstituted in 2.5 mM ammonium acetate in 75% methanol (aq), to analyse lipids. Amino acids were injected through a MicroLC system coupled to a QTRAP 6500 mass spectrometer (AB Sciex, MA, United States), and lipids were analysed using flow injection analysis. Data analysis was carried out using the Morpheus web application (https://software.broadinstitute. org/morpheus/).

# Metabolite extraction and LC-MS procedure for targeted metabolomics

Based on the successful but variable results obtained from the punches, we deemed it necessary to extract metabolites from the Schirmer strip until the tear front was reached. As a first step, metabolites were extracted from tears collected at all three time points from one study participant. These were pooled together to assess whether the MxP<sup>®</sup> Quant 500 kit and the AB SCIEX Triple Quad 5500+ mass spectrometer were feasible methods for targeted metabolomics. In the following experiments, one Schirmer strip from each participant (n = 26) at the three time points (n = 78) was cut into 5 mm pieces until the tear front was reached and placed into sterile tubes. A length-adjusted volume of ice-cold 80% methanol was added to each tube (500 µL per 46 mm Schirmer strip). Strips were vigorously vortexed in the extraction solution for 2 min before centrifugation at 15,700 relative centrifugal force (RCF) at 4°C. The supernatant was transferred to a fresh, clean tube and stored at  $-80^{\circ}$ C before analysis.

Targeted metabolomics profiling was performed using a commercially available kit,  $MxP^{\textcircled{}}$  Quant 500 kit (Biocrates Life Science AG, Innsbruck, Austria), which quantifies up to 624 metabolites/lipids from 26 analyte classes. All frozen tear samples ( $-80^{\circ}C$ ) were thawed on ice before preparation. According to the instruction from the kit manufacturer,  $10 \,\mu$ L of phosphate-buffered saline (PBS), calibrators, quality controls (QCs), and  $10 \,\mu$ L of tear samples were added to a 96-well plate which contains isotopic-labelled internal standards, dried under nitrogen at room temperature for 30 mins, followed by adding 50  $\mu$ L of phenylisothiocyanate (PITC) to derivatise amino acids and biogenic amines. After a further 20-min incubation at room temperature, samples were dried under nitrogen for 1 h. Ammonium acetate (3 mM) was added, and the plate was shaken at room temperature for 30 min and centrifuged for 2 min at

500 RCF. For LC-MS analysis, each well had 150 µL of extracts transferred to a 96-deep-well plate and an equal volume of dH<sub>2</sub>O. Metabolite separation was performed using an AB SCIEX ExionLC system (Foster, California, United States) with a reversed-phase MxP<sup>®</sup> Quant 500 UHPLC column and analysed using an AB SCIEX Triple Quad 5500+ mass spectrometer (Foster, California, United States) operating in the multiple reaction monitoring (MRM) mode. The injection volume is 5 µL. All the other metabolites (acylcarnitines, hexoses, glycerophospholipids, and sphingolipids) were quantified using the same mass spectrometer without column separation by the flow injection analysis (FIA) operating in MRM mode. A total of 10 µL of extract was mixed with 490 µL of FIA solvent in another 96-well plate at room temperature for 5 min. The injection volume is 20 µL. LC and FIA data were imported directly into the BIOCRATES software, MetIDQ Oxygen, and quantified for quantitation. Metabolite concentrations were calculated and expressed as micromoles (µM).

### Data analysis

Data clean-up was performed to select metabolites above the detection limit accurately (>LOD) for further analysis. Metabolites that fell between the upper and lower limits of quantification (ULOQ and LLOQ) were also identified and were classed as valid metabolites (upplementary Figure 2). To understand whether there were any differences in the metabolites found in tear biofluid from the participants in the BiZiFED study, dependent on dietary Zincol-2016 supplementation, it was important to determine the PZC of the individuals included in the metabolomics analysis. Blood plasma zinc concentrations for each individual were determined by ICP-MS and reported elsewhere (Brazier et al., 2020).

Metabolite concentrations were calculated, and a linear mixed effects model was used to correlate each participant's PZC at each time point to the paired tear metabolite concentrations. Here, we used time point (categorical) as a repeated measure and PZC (continuous) as a covariate of the metabolite concentration (continuous) as the dependent variable. Participant ID was applied as a random effect, and the  $\beta$ -coefficient prediction for the change in metabolite level per unit change in the levels of PZC was calculated using SPSS v29.0.0.0. Subsequently, to determine whether metabolite concentrations in tears responded to dietary zinc intervention, metabolite concentrations were normalised to the PZC of each participant at each time point and are expressed as micromoles per individual plasma zinc concentration (µM/[PZC]). Graphs of individual metabolites were plotted using GraphPad Prism software (v10.2.2). For analysis comparing metabolite concentrations pre- and postzinc intervention, outliers were removed from each dataset following the ROUT method of outlier identification (Q = 1%). Statistical analysis of metabolite concentrations in Zn-deficient participants compared to Zn-efficient participants was done through one-way Brown-Forsythe and Welch ANOVA comparison with Dunnett's T3 multiple comparisons testing. All other comparisons were through a pairwise t-test, or Wilcoxon signed rank test



to determine significance, dependent on D'Agostino & Pearson normality testing.

### Results

### Participant information

As reported elsewhere (Brazier et al., 2020), the average age of the participating women was  $35 \pm 7$  years, ranging between 22–48 years. Of the 47 participating women who completed the baseline data collection, all but one were illiterate, none were

taking contraceptives, and only one woman had reported receiving medication in the month preceding the study. Additionally, more than half of the women were overweight or obese (66%), with a mean  $\pm$  SD body mass index (BMI) at baseline of  $27.1 \pm 5.6$  kg/m<sup>2</sup>. Further details of the dietary diversity of the participating individuals can be found in the corresponding research article (Brazier et al., 2020).

Of the 50 participants who were initially enrolled into the BiZiFED study, five participants withdrew from the study due to unwillingness to provide repeat blood samples (n = 2), migration out of the area (n = 1), or severe illness (n = 2). The remaining 45 participants were all able to provide blood samples at each time point (Lowe et al., 2022) (Figure 1). Seven participants declined to provide tear samples at baseline, seven participants declined to provide tear samples at phase 1, and eight participants declined to provide tear samples at phase 2 (Figure 1). Overall, 33 participants provided tear samples at all three time points. The reasons for declining tear collection at different stages was not recorded.

# Targeted metabolomics is feasible from tear samples subjected to long-term storage

The first preliminary experiment assessed whether targeted metabolomics was feasible on tear samples collected in the field and subjected to long-term storage conditions. Metabolites extracted from these samples were compared qualitatively to those extracted from freshly collected tear samples. Using the MassChrom<sup>®</sup> kit for targeted metabolomics, we showed that the abundance of metabolites was qualitatively variable on the upper portion of the strip between the freshly collected and stored tear samples (Supplementary Figure S3). This highlighted that storing tear samples on Schirmer strips provided viable metabolites upon extraction but should not be directly compared to freshly collected tear samples.

The second preliminary experiment assessed whether metabolite extractions should occur from the upper or lower portion of the Schirmer strip (Supplementary Figure S1B). From five female participants from the BiZiFED study, upper and lower punches were analysed using the MassChrom<sup>®</sup> kit for targeted metabolomics. Metabolites extracted and detected were more abundant in the upper portion of the strip (Figure 2), although, some metabolites had equal abundance on both the upper and lower portions of the Schirmer strips (including leucine, butyrylcarnitine (C4-carnitine) and 3hydroxy-isovalerylcarnitine (C5OH-carnitine)) (Figure 2). This indicates that the Schirmer strip does not act as a chromatography system for all metabolites. We found intra-individual variabilities, as noted in the range of relative metabolite abundance found in the eyes of participant ID2 (Supplementary Figure S3A) and in participant ID1 (Supplementary Figure S3B). Variability in metabolite levels, such as we found in this study, has previously reported (Dammeier et al., 2018).

Based on the preliminary results, we determined that extracting metabolites from the entire Schirmer strip is necessary to provide as much metabolite coverage as possible in subsequent analysis. Next, we determined the number of metabolites we could detect in the BiZiFED samples. We used pooled tear samples (samples from the three time points) and analysed the metabolites present using the MxP<sup>®</sup> Quant 500 kit. This kit can quantify up to 624 metabolites, and we were able to identify 116 metabolites above the limit of detection (LOD) in the BiZiFED sample (Supplementary Figure S4A).

Next, we evaluated the number of analytes extracted from the 78 Schirmer strips we used from the BiZiFED study participant samples. We detected 67 metabolites after applying a strict validity cutoff ( $\geq$ 80% of samples above the metabolite LOD in any one analysis group ( $n \geq 10$ )) (Supplementary Figure S4A). Overall, 11 of the 23 available metabolite classes had at least one valid metabolite for further analysis (Supplementary Figure S4B).

# Metabolites found in tear fluid correlate inversely with plasma zinc concentrations

A linear mixed effects model was applied to determine whether there is a correlation between the concentration of metabolites found in tears and PZC (Figure 3). Two metabolites showed a weak but statistically significant correlation with PZC. Tiglylcarnitine (C5:1; N = 45) and valine (N = 40) were negatively correlated with PZC ( $\beta$ -coefficients =  $-8.01 \times 10^{-5}$  and  $-1.97 \times 10^{-3}$ , respectively; p = 0.0125 and 0.0409, respectively) (Figures 3A, B, respectively). A summary of the correlations for the metabolites and PZC can be found in Supplementary Table S1, including 95% confidence intervals.

# Metabolites found in tear fluid respond to dietary zinc intervention

We assessed whether dietary zinc intervention affected the metabolite abundances present in the tear fluid. Metabolite concentrations were normalised to each individual's PZC and then to each individual's respective baseline tear metabolite concentration. In total, nine metabolites showed a significant difference between baseline and post-zinc intervention (Figures 4A–I). Of these metabolites, acetylcarnitine (C2) (n = 20;  $1.87 \times 10^{-4}$  vs.  $1.18 \times 10^{-4} \mu$ M/[PZC]) glutamine (n = 23; 3.98  $\times$  10<sup>-3</sup> vs. 2.52  $\times$  10<sup>-3</sup>  $\mu M/[PZC]),$  two lysophosphatidylcholines (lysoPC a C16:0 (n = 25;  $3.17 \times 10^{-3}$  vs.  $2.26 \times 10^{-3} \mu$ M/[PZC]) and lyso a C18:1 (n = 23; 6.21 × 10<sup>-4</sup> vs. 4.28 × 10<sup>-4</sup>  $\mu$ M/[PZC])), and four sphingomyelins (SM (OH) C16:1 (n = 16; 1.98 × 10<sup>-5</sup> vs.  $1.36 \times 10^{-5} \ \mu M/[PZC])$ , SM C16:0 (*n* = 21; 7.19 × 10<sup>-4</sup> vs.  $4.19 \times 10^{-4} \ \mu M/[PZC]$ ), SM C16:1 (n = 23;  $1.98 \times 10^{-5}$  vs.  $1.40 \times 10^{-5} \ \mu M/[PZC])$ , and SM C24:0 (*n* = 22; 6.71 × 10<sup>-5</sup> vs. 4.48  $\times$  10<sup>-5</sup>  $\mu$ M/[PZC]) were all significantly downregulated (Figures 4A-H, respectively), and a ceramide (Cer(d18:1/18:0) was significantly upregulated (n = 15; 2.29 × 10<sup>-5</sup> vs. 3.74 ×  $10^{-5} \,\mu M/[PZC])$  (Figure 4I).

An additional comparison was made between metabolite abundances in the tears of all participants that were defined as having a low PZC (<660 µg/L) at their baselines (as per the iZINCG threshold (Brown et al., 2004)). Zinc intervention in this group resulted in significantly decreased concentrations of acetylcarnitine (C2) (n = 8; 1.92 × 10<sup>-4</sup> vs. 8.45 × 10<sup>-5</sup> µM/[PZC]) and glutamine (Gln) (n = 7; 2.43 × 10<sup>-3</sup> vs. 8.58 × 10<sup>-4</sup> µM/[PZC]) (Figures 5A, B, respectively).



### Metabolites found in tear fluid respond to dietary zinc intervention in a subpopulation of zinc-deficient individuals

The final set of comparisons were based on whether participants had PZC below or above the 660 µg/L iZINCG threshold for zinc deficiency. Four metabolites significantly differed at baseline (Figure 6). Hypaphorine (TrpBetaine) (n = 10-11; 5.96 × 10<sup>-5</sup> vs. 2.55 × 10<sup>-5</sup> µM/[PZC]), lauric acid (FA (12:0)) (n= 11–14; 1.87 × 10<sup>-2</sup> vs. 1.53 × 10<sup>-2</sup> µM/[PZC]), and indoxyl sulphate (Ind-SO<sub>4</sub>) (n = 11-15; 1.38 × 10<sup>-4</sup> vs. 1.09 × 10<sup>-4</sup> µM/[PZC])had significantly higher abundances (Figures 6A–C, respectively), whilst ceramide Cer(d18:1/24:1) was found at a significantly lower abundance (n = 10-12; 2.19 × 10<sup>-5</sup> vs. 6.41 × 10<sup>-5</sup> µM/[PZC]) (Figure 6D), in the tear fluid of zinc-deficient participants.

When dietary zinc intervention was provided to the zincdeficient participants (<660+Zn), the concentrations of hypaphorine  $(n = 10; 5.00 \times 10^{-5} \text{ vs. } 2.55 \times 10^{-5} \text{ } \mu\text{M}/[\text{PZC}])$  (Figure 6A), lauric acid (FA (12:0)) (n = 11-14;  $1.83 \times 10^{-2}$  vs.  $1.53 \times 10^{-2} \mu$ M/[PZC]) (Figure 6B), and indoxyl sulphate (Ind-SO<sub>4</sub>) (n = 11-15;  $1.30 \times 10^{-4}$ vs.  $1.09 \times 10^{-4} \,\mu\text{M}/[\text{PZC}])$  (Figure 6C) were no longer different from those that were zinc-efficient at baseline (>660) but ceramide Cer(d18:1/24:1) remained different (Figure 6D). In addition, zinc supplementation values (<660+Zn) did not significantly differ from the metabolite level in zinc-deficient participants (<660) at baseline (Figures 6A–C). Individual mean concentrations for these metabolites can be found in Supplementary Table S2 (baseline) and Supplementary Table S3 (post-zinc intervention). Further studies exploring whether these changes remain in a larger cohort will be required before the biological mechanism and clinical relevance of these metabolite changes in response to zinc can be elucidated.

### Discussion

Zinc homeostasis is critical for the healthy function of many biological processes, including, but not limited to,

growth, development, and neurological function or dysfunction. Importantly, zinc dysregulation has been shown to contribute to the development of progressive diseases such as age-related macular degeneration (AMD) and Alzheimer's disease (AD), and global health issues arising from micronutrient deficiency (Maynard et al., 2005; Flinn et al., 2014; Lowe, 2021). Increasing dietary zinc intake to overcome deficiencies and associated pathophysiological consequences in these diseases continues to interest researchers (Age-Related Eye Disease Study Research Group, 2001; Brewer, 2014; Awh et al., 2015; Lowe et al., 2020), and sensitive biomarkers of zinc status are required. However, biomarker detection often relies on invasive blood withdrawal, which can be problematic to obtain, store, and transport in field studies. In addition, blood zinc concentrations are a poor indicator of zinc status.

Tear sampling is inexpensive and well-tolerated, and the resulting samples are easy to handle (Quah et al., 2014). Tears contain biomarkers that overlap with those detected in the systemic circulation (Ravishankar and Daily, 2022). Combined with recent improvements in separation and detection techniques (Cicalini et al., 2019; Valencia et al., 2022), it is unsurprising that tear fluid collection is now becoming a feature of study protocols for global health studies (Singh et al., 2022).

Our first aim in this study was to assess the feasibility of collecting, storing, and transporting tear samples, from a fieldbased nutrition study, which must be evaluated first by comparing them to freshly collected tear samples. We found that field-based samples contained a variety of metabolites (116 metabolites) despite being collected 1 year before extraction, and they were subjected to multiple freeze-thaw cycles because they had to be collected, transported, and stored at multiple locations (Lowe et al., 2018). When metabolites were extracted from a single Schirmer strip, the number of metabolites detected was lower (67 metabolites), suggesting that some low-abundance metabolites might not be reliably detected from a single strip, a consideration for future studies. While planning the metabolite extraction from the tears collected on Schirmer strips, it became apparent that current



### FIGURE 4

Representative bar graphs of metabolites collected from tears in the BiZiFED study that showed a significant difference in abundance between baseline (before zinc intervention) and post-zinc intervention. Metabolites are: acetylcarnitine (C2) (A), glutamine (Gln) (B), lysophosphatidylcholines (lysoPC a C16:0 and lysoPC a C18:1) (C,D), respectively, sphingomyelins (SM (OH) C16:1, SM C16:0, SM C16:1, and SM C24:0) (E–H), respectively, and a ceramide (Cer(d18:1/18:0)) (I) (n = 15-25 tear samples per experimental condition, mean  $\pm$  S.D., \*p < 0.05, pairwise *t*-test (A–C,F–I), respectively or Wilcoxon signed rank test (D,E), respectively.



per experimental condition, mean + S.D., \*p < 0.05, \*p < 0.01, pairwise Wilcoxon signed rank test).

methods are not standardised, with each research article carrying out unique extraction and detection methods. This increases the difficulty of making inter-research group comparisons, as different extraction and detection methods will obtain varying metabolite classes and abundance of metabolites. The type of Schirmer strip used (García-Porta et al., 2018), sample handling (Qin et al., 2017), time to extraction, and extraction volumes (Gijs et al., 2023) can all influence detected biomarkers that have previously been obtained clinically. The Tear Research Network has recently been established to overcome these issues and develop clinically relevant standard operating procedures (https://tearresearchnetwork.com/).

Our second aim was to assess the relationship between plasma zinc concentrations and metabolite levels. Based on the results from 26 participants, our analysis revealed a significant negative correlation for two metabolites, tiglylcarnitine (C5:1) and valine, and PZC (Figure 3). Tiglylcarnitine is related to carnitine and is a member of the short-chain acylcarnitine group of metabolites. These have been suggested to be the most abundant group of acylcarnitines in human plasma (Dambrova et al., 2022) and carnitine levels in tears were associated with hyperosmolarity in dry eye diseases (Pescosolido et al., 2009). Elevated levels of tiglylcarnitine have been associated with liver zinc deficiency (Zheng et al., 2013). Valine concentrations have previously been shown to be increased in zinc-deficient rats (Hsu, 1977). It appears that our results agree with those inverse relationships between zinc and specific metabolites.

The third aim was to determine whether metabolites respond to dietary zinc intervention in the tear biofluid. First, we combined all selected participants (n = 26) before zinc intervention and compared them to those after zinc intervention. We found that the concentration of acetylcarnitine (C2), glutamine (Gln), two lysophosphatidylcholines (lysoPC a C16:0 and lysoPC

a C18:1), an hydroxysphingomyelin (SM (OH) C16:1), and three sphingomyelins (SM C16:0, SM C16:1, and SM C24:0) significantly decreased, and a ceramide (Cer(d18:1/18:0)) significantly increased, post-zinc dietary intervention (Figure 4). Next, we analysed metabolic changes in only those zinc deficient at baseline (PZC <660 µg/L, n = 10). Again, we found that acetylcarnitine (C2) and glutamine had significantly decreased following zinc intervention in this subset of study participants (Figure 5). Comparison of tear samples from participants with PZC <660 µg/L (n = 10), zinc-sufficient participants with PZC >660 µg/L (n = 16), and those with PZC <660 µg/L, but after zinc supplementation, showed no reversal of zinc deficiency-related metabolic changes (Figure 6). This suggests that metabolic changes might need more time to restore to the levels found in zinc-sufficient participants.

The physiological consequences of the metabolic changes identified after zinc intervention are not yet clear. However, it is important to consider that using the PZC to measure zinc deficiency is fraught with problems as total zinc measurement may not be a sensitive enough parameter for patient selection (Lowe et al., 2022). The metabolites that were detected in our study and showed significant differences pre- and post-zinc dietary intervention have all previously been detected in tear metabolomic studies (Borchman et al., 2007; Nakatsukasa et al., 2011; Rantamäki et al., 2011; Dean and Glasgow, 2012; Glasgow and Abduragimov, 2018; Du and Huang, 2019), highlighting their potential use as biomarkers for zinc status.

Importantly, this study showed that it is feasible to use the noninvasive and inexpensive tear fluid collection to assess changes in zinc nutrition, which can generate valuable data for monitoring the effectiveness and impact of interventions designed to improve dietary intake. Some limitations should be considered. Firstly, this



study used tear fluid obtained from a small cohort of individuals with additional limitations determined by the number of samples and metabolites that can be studied on the Biocrates MxP<sup>®</sup> 500 kit. It is also important to consider that using the PZC as a measure of zinc deficiency may not be a sensitive enough parameter for patient selection (Lowe et al., 2022). Using the data obtained from this study, a higher-powered study with a more targeted approach could be used to investigate metabolites that showed significant correlations with PZC or significant differences upon dietary zinc intervention.

In summary, we proved that it is feasible to carry out metabolite studies in field-based nutrition studies, using historically archived tear biofluid on Schirmer strips. After modified zinc nutrition there were significant differences in metabolites in both zinc sufficient and deficient patients. These might prove to biomarkers for zinc status in future studies. Given the wide-ranging role zinc plays in many biological processes (Costa et al., 2023; Shi et al., 2024), the availability of biomarkers could help refine intervention strategies. The diagnosis of zinc deficiency is challenging, and the search for a sensitive and specific biomarker has been ongoing for several decades. Further studies will help to define whether the metabolic changes reported here could be added to the list of zinc status biomarkers to increase sensitivity and specificity (Knez and Boy, 2023).

### Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: http://dx.doi.org/10. 21228/M8KT6Q.

### **Ethics statement**

The studies involving humans were approved by University of Central Lancashire & Khyber Medical University Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

### Author contributions

CB: Formal Analysis, Investigation, Writing-original draft, Writing-review and editing, Data curation, Methodology, Resources, Visualization. BS: Investigation, Writing-review and editing, Methodology, Resources. MZ: Investigation, Methodology, Writing-review and editing, Resources. XP: Investigation, Writing-review and editing, Data curation, Formal Analysis, Methodology, Resources. BG: Supervision, Writing-review and editing, Data curation, Formal Analysis, Investigation, Methodology, Resources. NL: Conceptualization, Funding acquisition, Methodology, Writing-review and editing, Investigation, Project administration, Resources, Supervision. IL: Conceptualization, Funding acquisition, Methodology, Supervision, Writing-review and editing, Investigation, Project administration, Resources.

## Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This BiZiFED project was funded by Biotechnology and Biological Sciences Research Council (BBSRC) Global Challenges Research Fund, Foundation Awards for Global Agriculture and Food Systems Research, Grant Number BB/P02338X/1. The Zincol-2016 seed was supplied by HarvestPlus and grown by Fauji Fertilizer Company. The Abaseen Foundation Pakistan facilitated the use of the health centre and access to the community. The Green laboratory is supported by grants from the Medical Research Council [MC PC 18038], Health and Social Care in Northern Ireland (HSCNI) [STL/5460/18], Department of Agriculture and Rural Development [19/R/702], The National Institutes of Health [NIH: R21AG067083/R33], and also the Higher Education Authority (Ireland) under the North-South Research Programme. The metabolite analysis was carried out with support from the Department for the Economy (DfE) funded PhD program.

### Acknowledgments

The authors would like to dedicate this study to Muhammad Jaffar Khan the original primary lead of the BiZiFED study in Pakistan who has died since the start of this study. We are also indebted to Heather Ohly for her contribution to database coordination. In addition, we would like to thank Lajos Csincsik and David Wright for their help with the statistical considerations.

## **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2024. 1421699/full#supplementary-material

## References

Abdulla, M. (1983). How adequate is plasma zinc as an indicator of zinc status? Prog. Clin. Biol. Res. 129, 171-183.

Age-Related Eye Disease Study Research Group (2001). A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Archives Ophthalmol. 119 (10), 1417–1436. doi:10.1001/archopht.119.10.1417

Awh, C. C., Hawken, S., and Zanke, B. W. (2015). Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the age-related eye disease study. *Ophthalmology* 122, 162–169. doi:10.1016/j.ophtha.2014.07.049

Borchman, D., Foulks, G. N., Yappert, M. C., Tang, D., and Ho, D. V. (2007). Spectroscopic evaluation of human tear lipids. *Chem. Phys. Lipids* 147 (2), 87-102. doi:10.1016/j.chemphyslip.2007.04.001

Brazier, A. K. M., Lowe, N. M., Zaman, M., Shahzad, B., Ohly, H., McArdle, H. J., et al. (2020). Micronutrient status and dietary diversity of women of reproductive age in rural Pakistan. *Nutrients* 12 (11), 3407. doi:10.3390/nu12113407

Brewer, G. J. (2014). Alzheimer's disease causation by copper toxicity and treatment with zinc. *Front. Aging Neurosci.* 6, 92. doi:10.3389/fnagi.2014.00092

Brown, K. H., Rivera, J. A., Bhutta, Z., Gibson, R. S., King, J. C., Lönnerdal, B., et al. (2004). International Zinc Nutrition Consultative Group (IZiNCG) technical document #1. Assessment of the risk of zinc deficiency in populations and options for its control. *Food Nutr. Bull.* 25 (1 Suppl. 2), S99–S203.

Chen, L., Zhou, L., Chan, E. C. Y., Neo, J., and Beuerman, R. W. (2011). Characterization of the human tear metabolome by LC-MS/MS. J. Proteome Res. 10 (10), 4876–4882. doi:10.1021/pr2004874

Cicalini, I., Rossi, C., Pieragostino, D., Agnifili, L., Mastropasqua, L., di Ioia, M., et al. (2019). Integrated lipidomics and metabolomics analysis of tears in multiple sclerosis: an insight into diagnostic potential of lacrimal fluid. *Int. J. Mol. Sci.* 20 (1265), 1265. doi:10.3390/ijms20061265

Costa, M. I., Sarmento-Ribeiro, A. B., and Gonçalves, A. C. (2023). Zinc: from biological functions to therapeutic potential. *Int. J. Mol. Sci.* 24 (5), 4822. doi:10.3390/ijms24054822

Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., et al. (2022). Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. *Pharmacol. Rev.* 74 (3), 506–551. doi:10.1124/pharmrev.121.000408

Dammeier, S., Martus, P., Klose, F., Seid, M., Bosch, D., D'Alvise, J., et al. (2018). Combined targeted analysis of metabolites and proteins in tear fluid with regard to clinical applications. *Transl. Vis. Sci. and Technol.* 7 (6), 22. doi:10.1167/tvst.7.6.22

Dean, A. W., and Glasgow, B. J. (2012). Mass spectrometric identification of phospholipids in human tears and tear lipocalin. *Investigative Ophthalmol. and Vis. Sci.* 53 (4), 1773–1782. doi:10.1167/iovs.11-9419

Du, C. X., and Huang, Z. (2019). Analysis of amino acids in human tears by hydrophilic interaction liquid chromatography and quadrupole Orbitrap mass spectrometry. *RSC Adv.* 9 (63), 36539–36545. doi:10.1039/c9ra05956c

e-Pact Consortium (2019). Evaluation of the supporting nutrition in Pakistan food fortification programme. Midterm evaluation report.

e-Pact Consortium (2021). Endline evaluation report. Evaluation of the supporting nutrition in Pakistan food fortification programme, foreign, commonwealth and development office.

Flinn, J. M., Kakalec, P., Tappero, R., Jones, B., and Lengyel, I. (2014). Correlations in distribution and concentration of calcium, copper and iron with zinc in isolated extracellular deposits associated with age-related macular degeneration. *Metallomics* 6 (7), 1223–1228. doi:10.1039/c4mt00058g

García-Porta, N., Mann, A., Sáez-Martínez, V., Franklin, V., Wolffsohn, J. S., and Tighe, B. (2018). The potential influence of Schirmer strip variables on dry eye disease characterisation, and on tear collection and analysis. *Contact Lens Anterior Eye* 41 (1), 47–53. doi:10.1016/j.clae.2017.09.012

Gijs, M., Arumugam, S., Van De Sande, N., Webers, C. A. B., Sethu, S., Ghosh, A., et al. (2023). Pre-analytical sample handling effects on tear fluid protein levels. *Sci. Rep.* 13 (1), 1317. doi:10.1038/s41598-023-28363-z

Glasgow, B. J., and Abduragimov, A. R. (2018). Interaction of ceramides and tear lipocalin. *Biochimica Biophysica Acta (BBA) - Mol. Cell Biol. Lipids* 1863 (4), 399–408. doi:10.1016/j.bbalip.2018.01.004

Gupta, S., Brazier, A. K. M., and Lowe, N. M. (2020). Zinc deficiency in low- and middle-income countries: prevalence and approaches for mitigation. *J. Hum. Nutr. Dietetics* 33 (5), 624–643. doi:10.1111/jhn.12791

Hsu, J. M. (1977). Zinc deficiency and alterations of free amino acid levels in plasma, urine and skin extract. *Prog. Clin. Biol. Res.* 14, 73–86.

Kassebaum, N. J., Jasrasaria, R., Naghavi, M., Wulf, S. K., Johns, N., Lozano, R., et al. (2014). A systematic analysis of global anemia burden from 1990 to 2010. *Blood* 123 (5), 615–624. doi:10.1182/blood-2013-06-508325

Khanna, R. K., Catanese, S., Emond, P., Corcia, P., Blasco, H., and Pisella, P.-J. (2022). Metabolomics and lipidomics approaches in human tears: a systematic review. *Surv. Ophthalmol.* 67 (4), 1229–1243. doi:10.1016/j.survophthal.2022.01.010

Knez, M., and Boy, E. (2023). Existing knowledge on Zn status biomarkers (1963–2021) with a particular focus on FADS1 and FADS2 diagnostic performance and recommendations for further research. *Front. Nutr.* 9, 1057156. doi:10.3389/fnut.2022.1057156

Knez, M., Graham, R. D., Welch, R. M., and Stangoulis, J. C. R. (2017). New perspectives on the regulation of iron absorption via cellular zinc concentrations in humans. *Crit. Rev. Food Sci. Nutr.* 57 (10), 2128–2143. doi:10.1080/10408398.2015.1050483

Lam, S. M., Tong, L., Duan, X., Petznick, A., Wenk, M. R., and Shui, G. (2014). Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles. *J. Lipid Res.* 55 (2), 289–298. doi:10.1194/jlr.M044826

Lam, S. M., Tong, L., Reux, B., Lear, M. J., Wenk, M. R., and Shui, G. (2013). Rapid and sensitive profiling of tear wax ester species using high performance liquid chromatography coupled with tandem mass spectrometry. *J. Chromatogr. A* 1308, 166–171. doi:10.1016/j.chroma.2013.08.016

Liere, M. v., Bhutta, Z., Hartvig-Blomberg, J., and Mahmood, S. (2017). *Embodying* the future: how to improve the nutrition status of adolescent girls in Pakistan, global alliance for improved nutrition (GAIN).

Lowe, N. M. (2016). Assessing zinc in humans. Curr. Opin. Clin. Nutr. and Metabolic Care 19 (5), 321–327. doi:10.1097/MCO.00000000000298

Lowe, N. M. (2021). The global challenge of hidden hunger: perspectives from the field. *Proc. Nutr. Soc.* 80 (3), 283–289. doi:10.1017/S0029665121000902

Lowe, N. M., Jaffar Khan, M., Broadley, M. R., Zia, M. H., McArdle, H. J., M Joy, E. J., et al. (2018). Examining the effectiveness of consuming flour made from agronomically biofortified wheat (Zincol-2016/NR-421) for improving Zn status in women in a lowresource setting in Pakistan: study protocol for a randomised, double-blind, controlled cross-over trial (BiZiFED). *BMJ Open 8*, e021364–21364. doi:10.1136/bmjopen-2017-021364

Lowe, N. M., Zaman, M., Khan, M. J., Brazier, A. K. M., Shahzad, B., Ullah, U., et al. (2022). Biofortified wheat increases dietary zinc intake: a randomised controlled efficacy study of zincol-2016 in rural Pakistan. *Front. Nutr.* 8, 809783. doi:10.3389/fnut.2021.809783

Lowe, N. M., Zaman, M., Moran, V. H., Ohly, H., Sinclair, J., Fatima, S., et al. (2020). Biofortification of wheat with zinc for eliminating deficiency in Pakistan: study protocol for a cluster-randomised, double-blind, controlled effectiveness study (BIZIFED2). *BMJ Open* 10 (11), e039231. doi:10.1136/bmjopen-2020-039231

Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R., and Li, Q. X. (2005). Metals and amyloid-beta in Alzheimer's disease. *Int. J. Exp. Pathology* 86, 147–159. doi:10.1111/j.0959-9673.2005.00434.x

Micha, R., Mannar, V., Afshin, A., Allemandi, L., Baker, P., Battersby, J., et al. (2020). 2020 global nutrition report: action on equity to end malnutrition.

Nakatsukasa, M., Sotozono, C., Shimbo, K., Ono, N., Miyano, H., Okano, A., et al. (2011). Amino acid profiles in human tear fluids analyzed by high-performance liquid chromatography and electrospray ionization tandem mass spectrometry. *Am. J. Ophthalmol.* 151 (5), 799–808. doi:10.1016/j.ajo.2010.11.003

Ohly, H., Broadley, M. R., Joy, E. J. M., Khan, M. J., McArdle, H., Zaman, M., et al. (2019). The BiZiFED project: biofortified zinc flour to eliminate deficiency in Pakistan. *Nutr. Bull.* 44 (1), 60–64. doi:10.1111/nbu.12362

Pakistan, G. o. (2019). National nutrition survey: final key findings report 2019. R. A. Coordination.

Pakistan, G. o., and UNICEF (2020). National nutrition survey 2018. Full report (3 volumes) and key findings report.

Pescosolido, N., Imperatrice, B., Koverech, A., and Messano, M. (2009). L-carnitine and short chain ester in tears from patients with dry eye. *Optometry Vis. Sci.* 86 (2), E132–E138. doi:10.1097/OPX.0b013e318194e767

Pingault, N., Caron, P., Kalafatic, C., Allahoury, A., Fresco, L. O., Kennedy, E., et al. (2017). Nutrition and food systems. A report by the high level panel of experts on food security and nutrition of the committee on world food security.

Qin, W., Zhao, C., Zhang, L., Wang, T., and Gao, Y. (2017). A dry method for preserving tear protein samples. *Biopreservation biobanking* 15 (5), 417-421. doi:10.1089/bio.2016.0117

Quah, J. H. M., Tong, L., and Barbier, S. (2014). Patient acceptability of tear collection in the primary healthcare setting. *Optometry Vis. Sci.* 91 (4), 452–458. doi:10.1097/OPX.00000000000188

Rantamäki, A. H., Seppänen-Laakso, T., Oresic, M., Jauhiainen, M., and Holopainen, J. M. (2011). Human tear fluid lipidome: from composition to function. *PLoS one* 6 (5), e19553. doi:10.1371/journal.pone.0019553

Ravishankar, P., and Daily, A. (2022). Tears as the next diagnostic biofluid: a comparative study between ocular fluid and blood. *Appl. Sci.* 12 (6), 2884. doi:10.3390/app12062884

Saville, J. T., Zhao, Z., Willcox, M. D. P., Blanksby, S. J., and Mitchell, T. W. (2010). Detection and quantification of tear phospholipids and cholesterol in contact lens deposits: the effect of contact lens material and lens care solution. *Investigative Ophthalmol. and Vis. Sci.* 51 (6), 2843–2851. doi:10.1167/iovs.09-4609

Shi, Y., Hao, R., Ji, H., Gao, L., and Yang, J. (2024). Dietary zinc supplements: beneficial health effects and application in food, medicine and animals. *J. Sci. Food Agric.* 104, 5660–5674. doi:10.1002/jsfa.13325

Singh, S., Srivastav, S., Mohamed, A., and Basu, S. (2022). Non-invasive tear film assessment in normal population: effect of age, sex, and interparametric relationship. *Front. Med.* 9, 894184. doi:10.3389/fmed.2022.894184

Sud, M., Fahy, E., Cotter, D., Azam, K., Vadivelu, I., Burant, C., et al. (2016). Metabolomics Workbench: an international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. *Nucleic Acids Res.* 44 (D1), D463–D470. doi:10.1093/nar/gkv1042 Valencia, E., García, M., Fernández-Vega, B., Pereiro, R., Lobo, L., and González-Iglesias, H. (2022). Targeted analysis of tears revealed specific altered metal homeostasis in age-related macular degeneration. *Investigative Ophthalmol. and Vis. Sci.* 63 (4), 10. doi:10.1167/iovs.63.4.10

Wen, X., Ng, T. K., Liu, Q., Wu, Z., Zhang, G., and Zhang, M. (2023). Azelaic acid and guanosine in tears improve discrimination of proliferative from non-proliferative diabetic retinopathy in type-2 diabetes patients: a tear metabolomics study. *Heliyon* 9 (5), e16109. doi:10.1016/j.heliyon.2023.e16109

Wessells, K. R., and Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. *PLoS ONE* 7 (11), e50568. doi:10.1371/journal.pone. 0050568

Zheng, J.-L., Luo, Z., Liu, C.-X., Chen, Q.-L., Zhu, Q.-L., Hu, W., et al. (2013). Differential effects of the chronic and acute zinc exposure on carnitine composition, kinetics of carnitine palmitoyltransferases I (CPT I) and mRNA levels of CPT I isoforms in yellow catfish *Pelteobagrus fulvidraco. Chemosphere* 92 (5), 616–625. doi:10.1016/j.chemosphere.2013.04.013